Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma (AIRCULES)
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Moderate-to-severe Asthma
Sponsor: Sanofi
Listed as NCT06102005, this PHASE2 trial focuses on Asthma and remains ongoing. Sponsored by Sanofi, it has been updated 18 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
18 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Mar 2026 [monthly]
Active Not Recruiting PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2025 — May 2025 [monthly]
Recruiting PHASE2
▶ Show 13 earlier versions
-
Jan 2025 — Mar 2025 [monthly]
Recruiting PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Feb 2024 [monthly]
Recruiting PHASE2
First recorded
Oct 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .